interleukin-22 igg2-fc
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 12, 2016 (NCT02406651)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-22Supplementation
IL22 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- interleukin-22 igg2-fc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02406651 | Phase 1/Phase 2 (Phase 2) | May 12, 2016 | Cornell University, Generon (Shanghai) Corporation Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Generon (Shanghai) Corporation Ltd. | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1